The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1463-1471

  Ling, Leong Uung ^a   Lin, Huimin ^a   Tan, Kuan Boone ^a   Chiu, Gigi N C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Colon cancer; Drug combination; Irinotecan; Protein kinase C; Safingol; Synergism

Indexed keywords

FLUOROURACIL; IRINOTECAN; MARCKS PROTEIN; PROTEIN KINASE C; SAFINGOL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; SPHINGOSINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; T LYMPHOCYTE; CELL SURVIVAL; COLON TUMOR; ENZYMOLOGY; METABOLISM; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL ADHESION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SYNERGISM; HT29 CELLS; HUMANS; PROTEIN KINASE C; SPHINGOSINE;

EID: 73949148215     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000465     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Rothenberg ML: Topoisomerase I inhibitors: review and update. Ann Oncol 8: 837-855, 1997.
3. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361: 2235-2242, 2003.
4. Fuchs C, Mitchell EP and Hoff PM: Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 32: 491-503, 2006.
5. Zhang N, Yin Y, Xu SJ and Chen WS: 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569, 2008.
6. Litvak D, Bilchik A and Cabot M: Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy. J Gastrointest Surg 7: 140-148, 2003.
7. Van Cutsem E and Blijham GH: Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Semin Oncol 26: 13-20, 1999.
8. Zeidan Y and Hannun Y: Translational aspects of sphingolipid metabolism. Trends Mol Med 13: 327-336, 2007.
9. Futerman AH and Hannun YA: The complex life of simple sphingolipids. EMBO Rep 5: 777-782, 2004.
10. Buehrer B and Bell R: Sphingosine kinase: properties and cellular functions. Adv Lipid Res 26: 59-67, 1993.
11. Schwartz G, Ward D, Saltz L, et al: A pilot clinical/ pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 3: 537-543, 1997.
12. Kedderis L, Bozigian H, Kleeman J, et al: Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol 25: 201-217, 1995.
13. Leclercq TM and Pitson SM: Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. IUBMB Life 58: 467-472, 2006.
14. Hannun Y, Loomis C, Merrill AJ and Bell R: Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 261: 12604-12609, 1986.
15. Michie A and Nakagawa R: The link between PKCalpha regulation and cellular transformation. Immunol Lett 96: 155-162, 2005.
16. Jarvis WD and Grant S: Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs 17: 227-240, 1999.
17. Hoffmann T, Leenen K, Hafner D, et al: Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs 13: 93-100, 2002.
18. Jarvis W, Fornari FJ, Tombes R, et al: Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol 54: 844-856, 1998.
19. Maurer B, Melton L, Billups C, Cabot M and Reynolds C: Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92: 1897-1909, 2000.
20. Sachs C, Safa A, Harrison S and Fine R: Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270: 26639-26648, 1995.
21. Schwartz G, Haimovitz-Friedman A, Dhupar S, et al: Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 87: 1394-1399, 1995.
22. Schwartz G, Jiang J, Kelsen D and Albino A: Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 85: 402-407, 1993.
23. Carvajal RD: A phase I clinical trial of safingol followed by cisplatin: Promising activity in refractory adrenocortical cancer with novel pharmacology. Proc Am Soc Clin Oncol 24: 13044, 2006.
24. Masur K, Lang K, Niggemann B, Zanker K and Entschladen F: High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 12: 1973-1982, 2001.
25. O'Brian CA, Ward NE, Gravitt KR and Gupta KP: The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. Prog Clin Biol Res 391: 117-120, 1995.
26. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
27. Nicoletti I, Migliorati G, Pagliacci M, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
28. Mayer L, Harasym T, Tardi P, et al: Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5: 1854-1863, 2006.
29. Jimeno A, Rudek M, Purcell T, et al: Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 61: 423-433, 2008.
30. Jones C, Clements M, Wasi S and Daoud S: Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest. Cancer Chemother Pharmacol 45: 252-258, 2000.
31. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U and Nishizuka Y: Direct activation of calcium-activated, phospholipiddependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257: 7847-7851, 1982.
32. Combadiere C, Pedruzzi E, Hakim J and Perianin A: A protein kinase inhibitor, staurosporine, enhances the expression of phorbol dibutyrate binding sites in human polymorphonuclear leucocytes. Biochem J 289: 695-701, 1993.
33. Ways DK, Kukoly CA, de Vente J, et al: MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 95: 1906-1915, 1995.
34. Sliva D, English D, Lyons D and Lloyd FP Jr: Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 290: 552-557, 2002.
35. Hamada M, Sumi T, Iwai S, Nakazawa M and Yura Y: Induction of endonuclease G-mediated apopotosis in human oral squamous cell carcinoma cells by protein kinase C inhibitor safingol. Apoptosis 11: 47-56, 2006.
36. Coward J, Ambrosini G, Musi E, et al: Safingol (L-threosphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 5: 184-193, 2009.
37. Villalona-Calero MA, Ritch P, Figueroa JA, et al: A phase I/II study of LY900003, an antisense inhibitor of protein kinase Calpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 10: 6086-6093, 2004.
38. Grossman SA, Alavi JB, Supko JG, et al: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol 7: 32-40, 2005.
39. Yuen AR, Halsey J, Fisher GA, et al: Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/ CGP 64128A) in patients with cancer. Clin Cancer Res 5: 3357-3363, 1999.
40. Schmitt M, Harbeck N, Thomssen C, et al: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997.
41. Noda T, Iwai S, Hamada M, Fujita Y and Yura Y: Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G. Apoptosis 14: 287-297, 2009.
42. Morales P, Dillehay D, Moody S, et al: Safingol toxicology after oral administration to TRAMP mice: demonstration of safingol uptake and metabolism by N-acylation and Nmethylation. Drug Chem Toxicol 30: 197-216, 2007.
43. Ramsay E, Dos Santos N, Dragowska W, Laskin J and Bally M: The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv 2: 341-351, 2005.
44. Batist G, Gelmon KA, Chi KN, et al: Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15: 692-700, 2009.
45. Tardi P, Johnstone S, Harasym N, et al: In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33: 129-139, 2009.